Related Experiment Video

Updated: Jun 14, 2026

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

Challenges to the development of new drugs and regimens for tuberculosis

Amina Jindani1, George E Griffin

  • 1Centre for Infection, Dept. of Cellular and Molecular Medicine, St. George's University of London, London, SW17 ORE. UK. ajindani@sgul.ac.uk

Tuberculosis (Edinburgh, Scotland)
|April 13, 2010
PubMed

Insights

Tuberculosis treatment duration needs shortening for better disease control. Complex clinical trial regulations threaten patient safety and drug development, requiring urgent guideline harmonization.

Area of Science:

  • Public Health
  • Infectious Diseases
  • Clinical Trial Management

Background:

  • Tuberculosis (TB) remains a significant global health challenge, with high prevalence, incidence, and mortality despite available treatments.
  • Reducing TB treatment duration is a key strategy for improving disease control, necessitating new drugs or optimized regimens.
  • Clinical trials are essential for evaluating the safety and efficacy of new TB treatments.

Purpose of the Study:

  • To highlight the critical need for shorter tuberculosis treatment durations.
  • To address the challenges posed by complex clinical trial regulations.
  • To advocate for the review and harmonization of clinical trial guidelines.

Main Methods:

  • Review of current challenges in tuberculosis treatment and clinical trial conduct.
  • Analysis of the impact of complex regulations on drug development and trial execution.
  • Discussion on the necessity of harmonizing guidelines for clinical trials.

Main Results:

  • Current tuberculosis treatment regimens may not be optimal for rapid control.
  • Increasing regulatory complexity can impede the progress of essential clinical trials.
  • Harmonization of guidelines is crucial for efficient and ethical trial conduct.

Conclusions:

  • Shortening tuberculosis treatment duration is vital for global health.
  • Streamlining clinical trial regulations is imperative to facilitate the development of new TB therapies.
  • Harmonized guidelines will ensure patient safety and accelerate the availability of effective treatments.

More Related Videos

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Tuberculosis01:23

Tuberculosis

Tuberculosis (TB) remains a significant global health concern, primarily targeting the lungs and spreading through airborne transmission. Infection begins when aerosolized droplet nuclei, expelled by an individual with active TB, are inhaled by another person. These microscopic particles carry Mycobacterium tuberculosis, the causative agent of TB. Upon reaching the alveoli, the bacilli are engulfed by alveolar macrophages. However, due to their specialized lipid-rich cell wall, these pathogens...
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Development of Antibiotic Resistance01:30

Development of Antibiotic Resistance

Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...